trending Market Intelligence /marketintelligence/en/news-insights/trending/xjt1t_hqo-mpyktzzjb61a2 content esgSubNav
In This List

Celltrion receives US FDA warning letter over manufacturing plant

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Celltrion receives US FDA warning letter over manufacturing plant

The U.S. Food and Drug Administration issued a warning letter to Celltrion Inc., noting concern at the South Korean company's manufacturing plant in Incheon.

Pfizer Inc.'s Inflectra is produced at the plant which the regulator said had certain issues related to manufacturing processes. Celltrion said the letter will not impact its production of Inflectra and that it will issue a full response within 15 days.

Inflectra is a biosimilar version of Johnson & Johnson's Remicade, which is used to treat autoimmune diseases including Crohn's disease, rheumatoid arthritis and plaque psoriasis.